+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, how the body processes, and the effects of a new drug called TRB-061, given as injections under the skin, in healthy adults and people with moderate-to-severe atopic dermatitis AD. This Phase 1a1b study includes healthy volunteers and patients to explore different dosing schedules and amounts in a randomized, double-blind, placebo-controlled setting. The study has three parts Part 1 involves healthy adults receiving a single dose of TRB-061 or placebo Part 2 includes healthy adults receiving three doses every 4 weeks over 8 weeks and Part 3 involves participants with moderate-to-severe AD receiving four doses every 4 weeks over 12 weeks. In Part 3, participants may also opt to switch treatments after the first period. Placebo doses match the appearance and schedule of TRB-061. Participants will attend multiple visits for dosing and follow-up, including safety checks, blood tests to measure drug levels, and assessments of side effects up to 12 weeks after dosing in Part 1, 10 weeks after dosing in Part 2, and through the end of the study in Part 3. Researchers will track adverse events, drug levels in the blood, and responses to treatment during the study, which runs until early 2028.

Age: 18Years - 70YearsAll GendersPhase 1
19 locations
P

Actively Recruiting

Researchers are evaluating the effects of MAR001 compared to a placebo in adults with elevated triglycerides TG and remnant cholesterol RC. This Phase 2b, randomized, double-blind, placebo-controlled study aims to understand how MAR001 impacts TG levels in people with specific cholesterol conditions. The study includes two parts, focusing on different ranges of baseline triglyceride levels to assess the treatments effects. Participants in Part A with TG levels between 150 and 880 mgdL will receive one of three doses of MAR001 or placebo by subcutaneous injection every four weeks. In Part B, participants with higher TG levels between 450 and 2000 mgdL will receive a dose chosen based on Part A results, also by subcutaneous injection every four weeks. The study consists of a screening period lasting up to 8 weeks, a 24-week treatment phase, and a 12-week safety follow-up with two clinic visits. During the trial, participants will undergo assessments including clinical visits at specified weeks, laboratory tests, and monitoring for safety and treatment effects. Researchers will measure changes in triglyceride levels primarily at 12 weeks, along with secondary outcomes at various time points. The total participation duration includes screening, treatment, and follow-up periods, allowing for comprehensive evaluation of MAR001s impact and safety in this population.

Age: 18Years - 75YearsAll GendersPhase 2
55 locations